Form 4: Gyre Therapeutics Director Acquires Stock Options

David M. Epstein, a director of Gyre Therapeutics, acquired stock options exercisable for 1,866 shares of common stock on August 6, 2024.

Summary

• On August 6, 2024, David M. Epstein, a director of Gyre Therapeutics, acquired stock options.
• The options are exercisable for 1,866 shares of common stock at a price of $10.79 per share.
• The options vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent upon continued service to the issuer.
• The expiration date for these options is August 6, 2034.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of stock option grants to a director, which is part of their compensation package.

Industry Context

This is a standard disclosure related to insider transactions, common for publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation and alignment of interests.

Key Dates